FDA Brief

Warning letters Drugs

FDA warning letter to

SCA Pharmaceuticals, LLC

High riskIssued Sep 14Posted Oct 13Center for Drug Evaluation and Research (CDER)

SCA Pharmaceuticals' sterile compounded drugs were made under unsanitary conditions with serious manufacturing violations, FDA says.

What happened

FDA inspected SCA Pharmaceuticals in Little Rock, Arkansas, from October 20 to October 30, 2025, and issued a Form FDA 483. The investigator found serious deficiencies in sterile drug production, including poor aseptic practices, inadequate airflow visualization and environmental monitoring, microbial contamination in an ISO 5 area, and foreign material in syringe stoppers. FDA reviewed the company’s November 21 and December 31, 2025 responses and found some corrective actions inadequate or not fully documented.

What FDA found

  1. Drugs intended to be sterile were prepared, packed, or held under unsanitary conditions that could contaminate them or make them harmful.

    FDCA § 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)]
  2. The firm did not establish and follow adequate written procedures to prevent microbial contamination, and technicians used poor aseptic practices that risked contamination of critical sterile areas.

    21 CFR 211.113(b)
  3. The aseptic processing areas lacked an adequate high-efficiency particulate air (HEPA) supply under positive pressure.

    21 CFR 211.42(c)(10)(iii)
  4. The firm did not thoroughly investigate unexplained discrepancies or batch failures, even after distribution.

    21 CFR 211.192
  5. The firm lacked adequate laboratory controls, specifications, sampling plans, and test procedures for components, containers, closures, in-process materials, labeling, and drug products.

    21 CFR 211.160(b)
  6. The quality control unit did not have or follow adequate written responsibilities and procedures; production video recordings used in investigations were not retained.

    21 CFR 211.22(d)

What FDA wants

Within 15 working days of receipt, notify FDA in writing of the specific steps taken to address the violations, with explanations and supporting documents, and state any reason for delay and a completion timeframe if needed. FDA also strongly recommends a comprehensive assessment of operations, including aseptic processing, with a third-party consultant with sterile drug manufacturing expertise.

Who should pay attention

  • clinics and hospitals that buy compounded sterile drugs
  • outsourcing facilities with aseptic operations
  • companies that rely on contract sterile compounders

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Pine Pharmaceuticals, LLC

    FDA cited outsourcing facility Pine Pharmaceuticals in Tonawanda, NY, for insanitary sterile compounding conditions and CGMP failures after a November 2025 inspection.

    High risk
  2. Fagron BV

    FDA warns Fagron's Canton, MA sterile compounding site over airflow, cleaning and investigation failures, prompting a recall.

    High risk
  3. RC Outsourcing, LLC

    FDA warned outsourcing facility RC Outsourcing of Lowellville, Ohio, that its sterile drugs were made under insanitary conditions that risk contamination.

    High risk
  4. Apothecary Pharma, LLC

    FDA warns Apothecary Pharma, an outsourcing facility, that its sterile compounded drugs were made under insanitary conditions.

    High risk